# A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

> **NCT04893759** · PHASE1 · TERMINATED · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 2 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Pelcitoclax

## Key facts

- **NCT ID:** NCT04893759
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-06
- **Primary completion:** 2022-09-14
- **Final completion:** 2022-09-14
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Company Strategy
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893759, "A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04893759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*